IMC-A12 added to irinotecan and cetuximab evaluated for metastatic colorectal cancer after oxaliplatin and bevacizumab failure

Despite advances, metastatic colorectal cancer (CRC) remains a significant challenge, particularly for patients whose disease progresses after first-line treatments like oxaliplatin and bevacizumab. These patients face limited therapeutic options and a poor prognosis, highlighting an urgent need for effective second-line strategies. Irinotecan and cetuximab represent a standard second-line regimen, targeting DNA topoisomerase I and the epidermal growth factor receptor (EGFR), respectively. This study explores whether adding IMC-A12, an insulin-like growth factor 1 receptor (IGF-1R) antibody, can improve outcomes by potentially overcoming resistance mechanisms or enhancing the efficacy of the existing regimen.

This Phase II clinical study aims to determine the value of adding IMC-A12 to a standard regimen of irinotecan and cetuximab. Participants are individuals diagnosed with metastatic colorectal cancer whose disease has progressed following initial treatment with oxaliplatin and bevacizumab. The study design involves comparing the efficacy and safety of irinotecan and cetuximab administered with IMC-A12 versus irinotecan and cetuximab alone. The primary objective is to assess the clinical benefit of this triple combination in a population with refractory disease.